AACP
KRYS icon

Advantage Alpha Capital Partners’s Krystal Biotech KRYS Stock Holding History

Advantage Alpha Capital Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,387
Closed -$421K – 66
2025
Q3 		$421K Sell
2,387
-507
-18% -$75.9K 0.13% 108
2025
Q2 		$398K Sell
2,894
-675
-19% -$99.1K 0.11% 105
2025
Q1 		$643K Buy
+3,569
New +$600K 0.16% 95
2024
Q4 		– Sell
-2,289
Closed -$417K – 170
2024
Q3 		$417K Buy
+2,289
New +$441K 0.09% 148

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advantage Alpha Capital Partners's KRYS Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 2,387 shares — an estimated $421K sold.

Advantage Alpha Capital Partners first reported a position in KRYS in Q3 2024 and held it in 4 quarters. The position peaked at $643K in Q1 2025. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 2,387 Krystal Biotech shares in Q4 2025, an estimated $421K.
  • Advantage Alpha Capital Partners first reported a position in Krystal Biotech in Q3 2024 and held it in 4 quarters.
  • Advantage Alpha Capital Partners's Krystal Biotech position peaked at $643K in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.